Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia
Fiona C Brownfoot, Roxanne Hastie, Natalie J Hannan, Ping Cannon, Tuong Nguyen, Laura Tuohey, Cathy Cluver, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
PLACENTA | W B SAUNDERS CO LTD | Published : 2020
INTRODUCTION: The antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are elevated in preeclampsia and have been implicated in its pathogenesis. We have previously demonstrated metformin and sulfasalazine independently reduce antiangiogenic factor secretion. Here we examined whether combining metformin and sulfasalazine may be more effective than either alone in reducing placental expression and secretion of antiangiogenic and angiogenic factors and the expression of markers of endothelial dysfunction. METHODS: We performed functional experiments using primary human placenta to explore the effect of metformin and sulfasalazine, at lower doses than p..View full abstract
Related Projects (2)
Awarded by NHMRC Early Career Fellowship (NHMRC)
Awarded by NHMRC
This work was funded by a Norman Beischer Medical Research Foundation grant. FB was supported by a NHMRC Early Career Fellowship (NHMRC #1142636). The NHMRC provided salary support (#1136418 to ST #1159261 to TKL). NJH was supported by a CR Roper Research Fellowship. The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.